Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SET domain-containing protein 9 (SETD9)
- Target
- SETD9
- Molecular classification
- Enzyme, Histone methyltransferase, Chromatin modifier, Epigenetic regulator
01
Overview
SET domain-containing protein 9 (SETD9) is part of a large family of proteins characterized by the presence of a SET domain, which imparts lysine methyltransferase activity. These enzymes regulate chromatin structure and gene transcription by methylating lysine residues on histones, a process central to epigenetic control. The SET domain, named after three Drosophila proteins (Su(var)3-9, Enhancer of zeste, and Trithorax), forms a unique knot-like structure that is distinct from classic methyltransferase folds[1][4]. SET domain-containing proteins are implicated in essential processes such as cell proliferation, growth control, and differentiation. While specific roles of SETD9 in disease are still emerging, the SET domain family, in general, has strong links to cancer biology and other transcriptional dysregulation disorders[1][5]. SETD9 may become increasingly relevant as a drug target and biomarker in the future.
- Other names
- SETD9
02
Mechanism of action
Inhibition of lysine methyltransferase activity (potential mechanism for drugs targeting SET domain proteins) Epigenetic modulation by altering chromatin methylation patterns
03
Biological functions
Histone lysine methylation (primarily associated with lysine methylation, contributing to the histone code)Regulation of gene transcription and chromatin structureEpigenetic control of gene functionCell proliferation, differentiation, and potentially growth control
04
Disease associations
Cancer (alterations in SET domain-containing proteins are linked to oncogenic changes)Other (regulation of transcription may implicate this family in a broad spectrum of diseases, but direct clinical evidence for SETD9 is limited)
05
Safety considerations
Potential for off-target effects due to the evolutionary conservation and widespread expression of SET domain-containing proteinsRisks associated with disruption of normal epigenetic regulation, including aberrant gene expression
06
Interacting drugs
No specific drugs are currently listed that directly target SETD9; however, histone methyltransferase inhibitors targeting the SET domain family are under development and exploration
07
Biomarkers
Expression levels of SETD9 or related methylation marks may be explored as biomarkers in cancer and other diseases
Beyond the preview
Go deeper on SET domain-containing protein 9 (SETD9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SET domain-containing protein 9 (SETD9).